Literature DB >> 22659962

Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients.

Terumoto Koike1, Teruaki Koike, Yasushi Yamato, Katsuo Yoshiya, Shin-Ichi Toyabe.   

Abstract

INTRODUCTION: Even for patients with clinical N0 non-small-cell lung cancer (NSCLC), several invasive tests are available to pathologically confirm the presumptive mediastinal stage by radiologic modalities. The aim of this study was to determine a high-risk population for mediastinal nodal metastasis in patients with clinical stage IA NSCLC, which would be suitable for mediastinal staging by invasive modalities, such as mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration.
METHODS: We retrospectively reviewed peripheral clinical stage IA NSCLC patients who had undergone surgical resection with systematic mediastinal lymphadenectomy from 1998 to 2011. To identify predictors for mediastinal nodal metastasis, univariate and multivariate logistic regression analyses were performed. For the significant factors, optimal cutoff points were determined with a receiver operating characteristic analysis.
RESULTS: Among the 894 patients eligible for this study, the overall prevalence of mediastinal nodal metastasis was 7.5%. The following four predictors for mediastinal nodal metastasis were identified: age, preoperative serum carcinoembryonic antigen level, tumor size on preoperative radiologic findings, and consolidation/tumor ratio on high-resolution computed tomography. Of the patients with all four predictors identified by the multivariate analyses and receiver operating characteristic analyses (age ≤ 67 years, carcinoembryonic antigen ≥ 3.5 ng/ml, tumor size ≥ 2.0 cm, and consolidation/tumor ratio ≥ 89%), the prevalence of mediastinal nodal metastasis was 33.8%.
CONCLUSIONS: Among the clinical stage IA NSCLC patients in whom all four predictors were identified, one third of the patients showed mediastinal nodal metastasis, and thus, those patients should be a target for mediastinal node assessment by invasive modalities, such as mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration.

Entities:  

Mesh:

Year:  2012        PMID: 22659962     DOI: 10.1097/JTO.0b013e31825871de

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  45 in total

1.  MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.

Authors:  Ji-Qun Geng; Xiao-Chen Wang; Long-Fei Li; Jun Zhao; Song Wu; Gui-Ping Yu; Kou-Jun Zhu
Journal:  Tumour Biol       Date:  2015-09-10

2.  External validation of a prediction model for pathologic N2 among patients with a negative mediastinum by positron emission tomography.

Authors:  Farhood Farjah; Leah M Backhus; Thomas K Varghese; James P Manning; Aaron M Cheng; Michael S Mulligan; Douglas E Wood
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

3.  Prediction Model for Nodal Disease Among Patients With Non-Small Cell Lung Cancer.

Authors:  Francys C Verdial; David K Madtes; Billanna Hwang; Michael S Mulligan; Katherine Odem-Davis; Rachel Waworuntu; Douglas E Wood; Farhood Farjah
Journal:  Ann Thorac Surg       Date:  2019-01-30       Impact factor: 4.330

4.  Recognition of "aggressive" behavior in "indolent" ground glass opacity and mixed density lesions.

Authors:  Junyan Zha; Dong Xie; Huikang Xie; Liping Zhang; Fangyu Zhou; Pengqing Ying; Lilan Zhao; Gening Jiang; Ke Fei; Chang Chen
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

5.  Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer.

Authors:  Feichao Bao; Ping Yuan; Xiaoshuai Yuan; Xiayi Lv; Zhitian Wang; Jian Hu
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

6.  Rebuttal from Dr. Obiols and Dr. Call.

Authors:  Carme Obiols; Sergi Call
Journal:  Transl Lung Cancer Res       Date:  2016-06

7.  Rebuttal from Dr. Decaluwé and Dr. Dooms.

Authors:  Herbert Decaluwé; Christophe Dooms
Journal:  Transl Lung Cancer Res       Date:  2016-06

8.  Pros: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Authors:  Carme Obiols; Sergi Call
Journal:  Transl Lung Cancer Res       Date:  2016-06

9.  A Prediction Model to Help with the Assessment of Adenopathy in Lung Cancer: HAL.

Authors:  Oisin J O'Connell; Francisco A Almeida; Michael J Simoff; Lonny Yarmus; Ray Lazarus; Benjamin Young; Yu Chen; Roy Semaan; Timothy M Saettele; Joseph Cicenia; Harmeet Bedi; Corrine Kliment; Liang Li; Sonali Sethi; Javier Diaz-Mendoza; David Feller-Kopman; Juhee Song; Thomas Gildea; Hans Lee; Horiana B Grosu; Michael Machuzak; Macarena Rodriguez-Vial; George A Eapen; Carlos A Jimenez; Roberto F Casal; David E Ost
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

10.  The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer.

Authors:  Carme Obiols; Sergi Call; Ramon Rami-Porta
Journal:  Transl Lung Cancer Res       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.